Overview

A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis

Status:
Not yet recruiting
Trial end date:
2025-02-10
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of JYP0061 in adult patients with moderate-to-severe atopic dermatitis. The main questions it aims to answer are: - The efficacy of JYP0061 in treating adult patients with moderate-to-severe atopic dermatitis. - The safety profile of JYP0061 when administered to adult patients with moderate-to-severe atopic dermatitis. Participants will: - Be treated with either a low-dose or high-dose of JYP0061. - Undergo efficacy and safety evaluations as stipulated in the trial protocol.
Phase:
Phase 2
Details
Lead Sponsor:
Guangzhou JOYO Pharma Co., Ltd
Collaborator:
Chengdu JOYO pharma Co., Ltd.